Ultragenyx Reports Record Q2 Revenue, Narrows Loss, Reaffirms 2026 Guidance with Key H2 Catalysts
RARE sits 50% above its 52-week low of $18.29.
Summary
Ultragenyx Pharmaceutical Inc. announced its second quarter 2026 financial results, reporting record quarterly revenue and a reduced net loss compared to the prior year, while reaffirming its full-year guidance and path to profitability in 2027. The company also highlighted multiple significant clinical and regulatory milestones expected in the second half of 2026.
Key Events · Earnings and Guidance · RARE
-
Record Quarterly Revenue Achieved
Ultragenyx reported $214 million in total revenue for Q2 2026, marking the highest quarterly revenue in the company's history.
-
Improved Q2 Net Loss
The company's net loss for Q2 2026 was $(92) million, or $(0.90) per share, an improvement compared to a net loss of $(115) million in Q2 2025.
-
Financial Guidance Reaffirmed
Management reaffirmed its full-year 2026 total revenue guidance of $730 million to $760 million and reiterated its path to profitability in 2027.
-
Two Gene Therapy PDUFA Dates Upcoming
The company has two Prescription Drug User Fee Act (PDUFA) action dates in H2 2026: August 23, 2026, for DTX401 (GSDIa) and September 19, 2026, for UX111 (MPS IIIA).
Analysis · RARE · Life Sciences
This 8-K details Ultragenyx's Q2 2026 financial performance, which saw record quarterly revenue and an improved net loss compared to the same period last year. While the company's cash balance has significantly decreased, management reaffirmed its full-year 2026 financial guidance and its commitment to achieving profitability in 2027. The report also provides critical updates on its pipeline, including two upcoming PDUFA dates for gene therapies and pivotal Phase 3 data for Angelman syndrome, which are major potential value drivers for the company in the near term.
At the time of this filing, RARE was trading at $27.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $18.29 to $39.89. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.